HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 09/19/2012 -- Orexigen Therapeu (NGM:OREX) is +0.46 - +8.39% from the previous close of $5.48. It traded between $5.41 - 5.98 with total traded volume of 4387893 shares. Keep a close eye on OREX, as the stock has been showing unusual moves over the past weeks. At Current market price, OREX has recovered +309.66% from its 52-week Low of 1.45 and has Pulled back -23.16% from its 52-week high of 7.73. Orexigen Therapeutics Inc. (OREX, $5.41, -$0.15, -2.70%) filed plans to offer as much as $150 million in mixed securities, which include stock and debt. The pharmaceutical company, which develops drug candidates for the treatment of obesity, recently had a market capitalization of roughly $393 million.
Should Investor Wait For Correction or Wait for Long : Click Here To Know More
Celldex Therapeut (NGM:CLDX) reported EPS of -1.05. For the Current Fiscal year, the company is expected to report EPS of -0.98. For the Next Quarter and Next Year, the company is expected to report EPS of -0.24 and -0.94 respectively. At Current Market Price, CLDX is in distance of +23.40% from its 50-day Moving Average price of $5.2108 and +35.70% from its 200-day Moving Average price of $4.7386. Companies such as CellDex Therapeutics (NASDAQ:CLDX), ImmunoCellular Therapeutics developing experimental therapies targeting brain tumors, can utilize MRI Interventions' technology as a direct delivery platform for their drugs. In facilitating the delivery of these, and other, experimental therapies, MRI Interventions creates risk-mitigated exposure to the future of treating neurologic diseases. As an intermediary in the delivery of therapeutics, MRI Interventions benefits from the recurring use of its technology, which drives revenues and cash-flows.
In an exclusive video interview, MRI Interventions Chief Executive Officer, Kimble Jenkins, discusses the company's outlook and growth prospects, utilization of ClearPoint - the company's MRI-guided visualization platform - and research & development efforts, particularly a next-generation visualization platform that will guide surgeons in catheter-based cardiac EP procedures.
Should Investor Buy or SEll This Stock : Find Out Here
BioSante Pharmace (NGM:BPAX) is +0.15 - +8.02% from the previous close of $1.87. It traded between $1.91 - 2.20 with total traded volume of 5586919 shares. Keep a close eye on BPAX, as the stock has been showing unusual moves over the past weeks. At Current market price, BPAX has recovered +66.94% from its 52-week Low of 1.21 and has Pulled back -87.85% from its 52-week high of 16.62. Biosante Pharmaceuticals Inc(NASDAQ:BPAX) shares soared 22.22% and closed at $1.87 in the last trading session. The company announced that the independent Data Monitoring Committee or DMC has completed the ninth unblinded review of the LibiGel Phase III cardiovascular events and breast cancer safety study. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. LibiGel is in development for the treatment of female sexual dysfunction or FSD, specifically, hypoactive sexual desire disorder or HSDD in menopausal women.
Can BPAX Continue Its Rally? Find Out Here
Geron Corporation (NasdaqNM:GERN) is +0.11 - +7.69% from the previous close of $1.43. It traded between $1.41 - 1.56 with total traded volume of 3002122 shares. Keep a close eye on GERN, as the stock has been showing unusual moves over the past weeks. At Current market price, GERN has recovered +27.27% from its 52-week Low of 1.21 and has Pulled back -48.49% from its 52-week high of 2.99. Geron Corporation (GERN) shares gained 1.42% to $1.43 after the company announced the appointment of Andrew J. Grethlein, Ph.D., as Executive Vice President of Technical Operations. Dr. Grethlein will oversee the Company's manufacturing and quality functions. Dr. Grethlein joins Geron from Inspiration Biopharmaceuticals, where he was Executive Vice President and Chief Operating Officer from 2010 to 2012.
Can GERN Continue Its Rally? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)